Fig. 7.

ITGA6 expression levels are prognostic of overall or recurrence-free survival of breast cancer patients. a ITGA6 mRNA is differentially expressed in human breast cancers classified by the PAM50 subtype in the TCGA data set [30]; ***p < 0.001, ANOVA with Bonferroni post-test; (n = 93 basal, 56 HER2+, 228 Luminal A, 123 Luminal B and 7 normal-like tumors). b ITGA6 mRNA levels also weakly positively correlate with HIF1A levels (p <0.05, correlation coefficient r ² = 0.0078; TCGA data), but not with HIF2A mRNA levels (p = 0.08). c-d Kaplan-Meier curves depict the probability of overall survival (c) or recurrence-free survival (d) based on relative ITGA6 mRNA expression from clinical data reported in [42]. ITGA6 expression levels were stratified by the upper quartile or lowest quartiles (n = 37 tumors for “High” CD49f expression, and n = 45 tumors for “Low CD49f”) and significance determined by the log-rank test, *p < 0.05)